Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT00070304
First received: October 3, 2003
Last updated: July 25, 2013
Last verified: July 2013